Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.

Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome. For more information please click here.

By |January 24th, 2017|Recent News|

Therabron Therapeutics to Present at Stifel 2016 Healthcare Conference

ROCKVILLE, MD, November 10, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that its President and Chief Executive […]

By |November 10th, 2016|Recent News|

Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants

ROCKVILLE, MD, June 2, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that the U.S. Food and Drug […]

By |June 2nd, 2016|Recent News|

Therabron Therapeutics to Present at Upcoming Industry and Investor Conferences

ROCKVILLE, MD, June 1, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that President and Chief Executive Officer, […]

By |June 1st, 2016|Recent News|

Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants

ROCKVILLE, MD, May 25, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced the Company has completed enrollment of its […]

By |May 25th, 2016|Uncategorized|

Therabron Therapeutics Appoints Global Pulmonary Experts to the Company’s Scientific Advisory Board

ROCKVILLE, MD, May 19, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, announced today the appointment of four world-renowned experts to […]

By |May 19th, 2016|Recent News|

Therabron Therapeutics Announces Scientific Presentations at the American Thoracic Society (ATS) 2016 International Conference

ROCKVILLE, MD, May 11, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that Aprile Pilon, PhD, Chief Scientific Officer […]

By |May 11th, 2016|Recent News|

Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth

ROCKVILLE, MD, April 28, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, announced today that it has received Fast Track Designation […]

By |April 28th, 2016|Uncategorized|

Therabron Therapeutics to Present at World Orphan Drug Congress USA 2016

ROCKVILLE, MD, April 19, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that Dr. Thomas F. Miller, President […]

By |April 20th, 2016|Uncategorized|

Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform

Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that it has received Notice of Allowance from the United States Patent […]

By |April 13th, 2016|Recent News|